-
Debate weighs whether BMI should remain central to obesity diagnosis
Francesco Rubino, MD, spoke in favor of moving beyond body mass index in diagnosing obesity. Leigh Perreault, MD, defended the long-time cornerstone of obesity diagnosis.
-
Experts share the latest updates on the Standards of Care in Overweight and Obesity
The growing document provides evidence-based, unified guidance and actionable recommendations. Leigh Perreault, MD, presented a new chapter on screening diagnosis. Louis J. Aronne, MD, FACP, shared a new chapter on obesity medications.
-
Expert panel addresses GLP-1 RAs’ factors, features, and future
Amid increasing attention for GLP-1 RAs, a panel of experts summarized a broad spectrum of topics related to these medications, including emerging pharmacological options, muscle physiology, obesity treatment for osteoarthritis, and nutritional counseling.
-
Glucagon/GLP-1 receptor dual agonist demonstrates efficacy for obesity and MASLD
Matthias H. Tschöp, MD, and other researchers detailed phase 3 results of SYNCHRONIZE-1 and SYNCHRONIZE-MASLD showing that survodutide leads to significant weight loss, reduction in liver fat, and other health improvements.
-
Triple-hormone therapy demonstrates efficacy for type 2 diabetes and obesity
Activation of the glucagon receptor with retatrutide is being investigated in a large phase 3 program that includes 14 trials and more than 22,000 participants. Researchers, including Ania Jastreboff, MD, PhD, shared data from two of the trials, TRANSCEND-T2D-1 and TRIUMPH-1.
-
Dual GLP-1/GIP receptor agonist improves glycemic management and weight loss in adults living with type 1 diabetes and obesity
Klara Klein, MD, PhD, and other researchers shared results from a phase 2, double-blind, randomized study of acmopatide. Study participants also experienced improvements in blood pressure and insulin dosing.
-
Positive data from multiple amylin trials draw focus to novel therapeutic mechanism
Investigators, including Carel le Roux, MBChB, FRCP, FRCPath, PhD, discussed findings from monotherapy and combination trials with the pancreatic beta cell hormone. “Not only are these weight loss drugs, these are also health-gain drugs,” Dr. le Roux said.
-
Ultra-long-acting GLP-1 RA improves weight loss in individuals with and without type 2 diabetes
A Scientific Sessions panel shared new data from the VESPER trials. The long half-life of berobenatide makes investigators optimistic about its potential for monthly dosing.
-
Session to address the economic and health value of obesity treatment
Panelists, including Tim Dall, MS, will help make business and social cases for investing in evidence-based treatment for obesity, such as lower healthcare costs, improved quality of life, and reduced mortality.
-
Panel to review the impact of disordered eating in diabetes and obesity
Nicole Patience, MS, RDN, LDN, CEDS-C, CDCES, and other experts will explain how eating disorders and imbalanced eating can affect people living with diabetes or obesity and how to help them achieve sustainable wellness.